Evidence map›Paper›PMID 33933481›Full record

ArticleInternational journal of radiation oncology, biology, physics2021

Coadministration of a Clinically Relevant Dexamethasone Dosage With Ablative Radiation Therapy Reduces Peripheral Lymphocytes But Does Not Alter In Vivo Intratumoral Lymphocyte Phenotype or Inhibit Efficacy of Radiation Therapy in a Murine Colorectal Tumor Model.

Nicholas G Battaglia, Taylor P Uccello, Angie Hughson, Jesse Garrett-Larsen, Johnathan J Caldon, Haoming Qiu, Scott A Gerber, Edith M Lord

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nicholas G BattagliaDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Taylor P UccelloDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Angie HughsonDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Jesse Garrett-LarsenDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Johnathan J CaldonDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Haoming QiuDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, New York.
Scott A GerberDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Edith M LordDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York. Electronic address: edith_lord@urmc.rochester.edu.
University of Rochester Medical Center · US

Funding

The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
IN SITU ANTITUMOR IMMUNITY AND EFFECTS OF RADIATIONR01CA028332 · NCI · UNIVERSITY OF ROCHESTER · PI LORD, EDITH M · 1985 to 2020
$5.0M
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune responseR01CA236390 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GERBER, SCOTT ANDREW, REPASKY, ELIZABETH A · 2019 to 2023
$2.8M
Development of a New Strategy to Treat Locally Advanced Pancreatic CancerR01CA230277 · NCI · UNIVERSITY OF ROCHESTER · PI GERBER, SCOTT ANDREW · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA028332NCI NIH HHS R01 CA230277NCI NIH HHS R01 CA236390NIAID NIH HHS T32 AI007285
6 · The paper itself

Abstract

purposeDexamethasone is commonly given during radiation therapy (RT) to manage toxicities. Our study examines if dexamethasone coadministration with RT inhibits the RT-induced antitumor T cell response in mouse. METHODS AND MATERIALS: Intramuscularly implanted MC38 tumors were irradiated with 15 Gy after establishing for 7 days. Tumor bearing mice were administered dexamethasone using multiple schedules and doses. Peripheral lymphocyte reduction was monitored by complete blood count and intratumoral and tumor draining lymph node (tdLN) populations by flow cytometry. Effector phenotype and function of ex vivo stimulated tumor-infiltrating lymphocytes (TILs) and naïve splenocytes as well as in vivo TILs with or without dexamethasone were monitored by flow cytometry and ELISA.

resultsLong course high dose, short course high dose, and short course human equivalent dose dexamethasone reduced peripheral lymphocytes yet did not inhibit survival after irradiation. Short course high dose administration decreased TIL and tdLN lymphocyte activation as well as tdLN mass but did not affect TIL frequencies or change tdLN cell population composition. Dexamethasone inhibited effector function of ex vivo stimulated naïve splenocytes and TILs, but magnitude of IFN-γ secretion was consistently higher in TILs regardless of dexamethasone dose. In vivo analysis of TILs after irradiation and HE dexamethasone treatment showed that TILs had a similar effector phenotype compared with vehicle controls.

conclusionsDexamethasone reduces blood and tdLN lymphocytes. Dexamethasone also suppresses TIL activation/effector function yet does not affect survival in irradiated MC38 tumor bearing mice, which depend on RT-induced immune responses for therapy efficacy. Additional study in human subjects is warranted.

Indexed as

AnimalsColorectal NeoplasmsDexamethasoneInterferon-gammaLymph NodesLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLPhenotypeDexamethasoneInterferon-gamma

Identifiers

PMID33933481
PMCPMC9154044
OpenAlexW3157815855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.